Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2571) 2571
Newspaper Article (418) 418
Publication (290) 290
Book Chapter (60) 60
Book Review (36) 36
Book / eBook (14) 14
Dissertation (9) 9
Web Resource (6) 6
Conference Proceeding (5) 5
Magazine Article (5) 5
Trade Publication Article (4) 4
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cannabidiol (2280) 2280
index medicus (1076) 1076
humans (961) 961
animals (910) 910
male (745) 745
cannabinoids (743) 743
pharmacology & pharmacy (700) 700
cannabidiol - pharmacology (666) 666
marijuana (561) 561
cannabis (522) 522
neurosciences (461) 461
mice (442) 442
tetrahydrocannabinol (391) 391
rats (366) 366
female (339) 339
cannabidiol - therapeutic use (304) 304
clinical neurology (301) 301
dronabinol - pharmacology (295) 295
psychiatry (281) 281
cannabinoids - pharmacology (268) 268
delta-9-tetrahydrocannabinol (258) 258
delta-tetrahydrocannabinol (244) 244
epilepsy (234) 234
endocannabinoid system (219) 219
analysis (216) 216
dose-response relationship, drug (214) 214
pharmacology (209) 209
adult (208) 208
medical marijuana (196) 196
thc (196) 196
cannabidiol - administration & dosage (190) 190
cannabinoid (189) 189
drug combinations (176) 176
anandamide (153) 153
pain (149) 149
multiple sclerosis (146) 146
disease models, animal (142) 142
hemp (139) 139
cannabinoids - therapeutic use (137) 137
cbd (137) 137
research (137) 137
biochemistry & molecular biology (135) 135
receptors (135) 135
anxiety (134) 134
inflammation (134) 134
middle aged (134) 134
dronabinol (133) 133
health aspects (133) 133
cannabis - chemistry (130) 130
neurology (129) 129
schizophrenia (129) 129
brain (126) 126
care and treatment (126) 126
receptor (124) 124
expression (122) 122
cannabinoid receptor (121) 121
treatment outcome (121) 121
cannabinoid receptors (120) 120
double-blind (119) 119
seizures (118) 118
time factors (117) 117
in-vitro (113) 113
dronabinol - therapeutic use (112) 112
endocannabinoids (112) 112
activation (107) 107
oxidative stress (107) 107
plant extracts - therapeutic use (107) 107
article (106) 106
multiple sclerosis - drug therapy (105) 105
dronabinol - administration & dosage (104) 104
multiple-sclerosis (104) 104
drug therapy (101) 101
spasticity (100) 100
rats, wistar (99) 99
cannabinol (95) 95
drug interactions (95) 95
inhibition (95) 95
dronabinol - analogs & derivatives (93) 93
cancer (92) 92
clinical trials (92) 92
psychosis (92) 92
drugs (91) 91
behavioral sciences (88) 88
mental disorders (88) 88
muscle spasticity - drug therapy (88) 88
apoptosis (87) 87
cb1 (87) 87
neuroprotection (87) 87
double-blind method (86) 86
usage (86) 86
rat (85) 85
cannabidiol - analysis (84) 84
δ9-tetrahydrocannabinol (84) 84
adolescent (83) 83
dronabinol - analysis (83) 83
brain - drug effects (82) 82
cannabidiol - adverse effects (82) 82
young adult (82) 82
medicine (81) 81
pharmacokinetics (80) 80
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2864) 2864
Spanish (117) 117
German (30) 30
French (20) 20
Japanese (12) 12
Chinese (9) 9
Portuguese (8) 8
Hungarian (4) 4
Danish (3) 3
Polish (3) 3
Italian (2) 2
Norwegian (2) 2
Korean (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Untargeted rat brain metabolomics after oral administration of a single high dose of cannabidiol
by Citti, Cinzia and Palazzoli, Federica and Licata, Manuela and Vilella, Antonietta and Leo, Giuseppina and Zoli, Michele and Vandelli, Maria Angela and Forni, Flavio and Pacchetti, Barbara and Cannazza, Giuseppe
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 11/2018, Volume 161, pp. 1 - 11
Cannabidiol (CBD), for long time considered as a minor cannabinoid of , has recently gained much attention due to its antioxidant, anti-inflammatory, analgesic... 
Metabolomics | Cannabidiol | Liquid chromatography | Cannabidiol metabolites | Mass spectrometry | Cannabidiol pharmacokinetics | CONSTITUENT | CHEMISTRY, ANALYTICAL | METABOLITES | TANDEM MASS-SPECTROMETRY | IDENTIFICATION | LIVER | DELTA-TETRAHYDROCANNABINOL | PHARMACOLOGY & PHARMACY | GENERATION | CANNABINOIDS | Brain - metabolism | Cannabidiol - analysis | Animals | Chromatography, High Pressure Liquid - methods | Cannabidiol - administration & dosage | Dronabinol - analogs & derivatives | Rats | Cannabidiol - analogs & derivatives | Cannabidiol - pharmacokinetics | Tandem Mass Spectrometry - methods | Dronabinol - analysis | Antioxidants | Brain | Marijuana | Metabolites
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Cannabidiol (CBD) and its analogs: a review of their effects on inflammation
by Burstein, Sumner
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 04/2015, Volume 23, Issue 7, pp. 1377 - 1385
First isolated from in 1940 by Roger Adams, the structure of CBD was not completely elucidated until 1963. Subsequent studies resulted in the pronouncement... 
CBD receptor binding | Δ9-Tetrahydrocannabinol | Signaling events | Downstream events | Cannabidiol | Functional effects | Anti-inflammatory | Tetrahydrocannabinol | COLLAGEN-INDUCED ARTHRITIS | ANTIINFLAMMATORY ACTIVITY | OXIDATIVE STRESS | CHEMISTRY, MEDICINAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | CHEMISTRY, ORGANIC | CONSTITUENT CANNABIDIOL | STERIC INTERFERENCE | Delta-Tetrahydrocannabinol | ADENOSINE RECEPTORS | BV-2 MICROGLIAL CELLS | CANNABINOID RECEPTOR | MULTIPLE-SCLEROSIS | AJULEMIC ACID | Protein Structure, Tertiary | Inflammation - pathology | Inflammation - metabolism | Animals | Inflammation - drug therapy | Humans | Inflammation Mediators - metabolism | Cannabidiol - analogs & derivatives | Treatment Outcome | Cannabidiol - therapeutic use | Inflammation Mediators - antagonists & inhibitors | Cannabidiol - chemistry
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents
by Fasinu, Pius S and Phillips, Sarah and ElSohly, Mahmoud A and Walker, Larry A
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, ISSN 0277-0008, 07/2016, Volume 36, Issue 7, pp. 781 - 796
States and the federal government are under growing pressure to legalize the use of cannabis products for medical purposes in the United States. Sixteen states... 
cannabidiol | cannabis | drug development | medical marijuana | 9‐tetrahydrocannabinol | tetrahydrocannabinol | Delta-tetrahydrocannabinol | CLINICAL-TRIAL | ANANDAMIDE | SCHIZOPHRENIA | SYMPTOMS | ENDOCANNABINOIDS | PHARMACOLOGY | PHARMACOLOGY & PHARMACY | EPILEPSY | CANNABINOIDS | CB1 RECEPTORS | HISTORY | Endocannabinoids - physiology | Cannabidiol - toxicity | Humans | Receptors, Cannabinoid - physiology | Cannabidiol - pharmacology | Epilepsy - drug therapy | Cannabidiol - pharmacokinetics | Cannabidiol - therapeutic use | Epilepsies, Myoclonic - drug therapy | Lennox Gastaut Syndrome - drug therapy | Dronabinol - therapeutic use | Medical marijuana | Health aspects | Pharmaceutical industry | Prescription drugs | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Cannabidiol Claims and Misconceptions
by Russo, Ethan B
Trends in Pharmacological Sciences, ISSN 0165-6147, 2016, Volume 38, Issue 3, pp. 198 - 201
Once a widely ignored phytocannabinoid, cannabidiol now attracts great therapeutic interest, especially in epilepsy and cancer. As with many rising trends,... 
Advanced Basic Science | PHARMACOLOGY & PHARMACY | DELTA-9-TETRAHYDROCANNABINOL | THC | Cannabis - chemistry | Humans | Cannabidiol - pharmacology | Cannabidiol - therapeutic use | Cannabis - metabolism | Cannabidiol - metabolism | Cannabidiol - chemistry
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text DMH-CBD, a cannabidiol analog with reduced cytotoxicity, inhibits TNF production by targeting NF-kB activity dependent on A2A receptor
by Silva, Rangel L and Silveira, Gabriela T and Wanderlei, Carlos W and Cecilio, Nerry T and Maganin, Alexandre G.M and Franchin, Marcelo and Marques, Lucas M.M and Lopes, Norberto P and Crippa, José A and Guimarães, Francisco S and Alves-Filho, José C.F and Cunha, Thiago M and Cunha, Fernando Q
Toxicology and Applied Pharmacology, ISSN 0041-008X, 04/2019, Volume 368, pp. 63 - 71
Cannabidiol (CBD) is a natural compound with psychoactive therapeutic properties well described. Conversely, the immunological effects of CBD are still poorly... 
Cannabidiol | DHM-Cannabidiol | Macrophages | TNF | NF-kB
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text DMH-CBD, a cannabidiol analog with reduced cytotoxicity, inhibits TNF production by targeting NF-kB activity dependent on A 2A receptor
by Silva, Rangel L and Silveira, Gabriela T and Wanderlei, Carlos W and Cecilio, Nerry T and Maganin, Alexandre G.M and Franchin, Marcelo and Marques, Lucas M.M and Lopes, Norberto P and Crippa, José A and Guimarães, Francisco S and Alves-Filho, José C.F and Cunha, Fernando Q and Cunha, Thiago M
Toxicology and Applied Pharmacology, ISSN 0041-008X, 04/2019, Volume 368, pp. 63 - 71
Cannabidiol (CBD) is a natural compound with psychoactive therapeutic properties well described. Conversely, the immunological effects of CBD are still poorly... 
Cannabidiol | DHM-Cannabidiol | Macrophages | TNF | NF-kB
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Cannabidiol, neuroprotection and neuropsychiatric disorders
by Campos, Alline C and Fogaça, Manoela V and Sonego, Andreza B and Guimarães, Francisco S
Pharmacological Research, ISSN 1043-6618, 10/2016, Volume 112, pp. 119 - 127
Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from . It has possible therapeutic effects over a broad range of neuropsychiatric... 
Oxidative stress | Cannabidiol | Neuropsychiatric disorders | 5HT1A receptor | PPAR-γ receptor | Endocannabinoids | PERIAQUEDUCTAL GRAY | 5-HT1A RECEPTORS | PPAR-gamma receptor | MULTIPLE-SCLEROSIS | STRIA TERMINALIS | CHRONICALLY STRESSED MICE | IN-VIVO | BEHAVIOR INVOLVEMENT | PHARMACOLOGY & PHARMACY | NF-KAPPA-B | DEPRESSION FOCUS | Neuroprotective Agents - therapeutic use | Neuroprotection | Cannabidiol - administration & dosage | Humans | Cannabidiol - pharmacology | Clinical Trials as Topic | Drug Discovery | Brain Diseases - drug therapy | Animals | Neuroprotective Agents - pharmacology | Mental Disorders - drug therapy | Cannabidiol - therapeutic use | Neuroprotective Agents - administration & dosage | Nervous system diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
by McGuire, Philip and Robson, Philip and Cubala, Wieslaw Jerzy and Vasile, Daniel and Morrison, Paul Dugald and Barron, Rachel and Taylor, Adam and Wright, Stephen
American Journal of Psychiatry, ISSN 0002-953X, 03/2018, Volume 175, Issue 3, pp. 225 - 231
Objective:Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness... 
ANXIETY | PSYCHIATRY | PHARMACOLOGY | PSYCHOSIS | MECHANISMS | SYMPTOMS | THC | Cannabidiol - administration & dosage | Double-Blind Method | Antipsychotic Agents - adverse effects | Humans | Male | Antipsychotic Agents - administration & dosage | Psychiatric Status Rating Scales | Antipsychotic Agents - therapeutic use | Cannabidiol - adverse effects | Adult | Female | Cannabidiol - therapeutic use | Schizophrenia - drug therapy | Drug Therapy, Combination | Schizophrenia | Cannabinoids | Dosage and administration | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
by Devinsky, Orrin, Dr Prof and Marsh, Eric, MD and Friedman, Daniel, MD and Thiele, Elizabeth, Prof and Laux, Linda, MD and Sullivan, Joseph, MD and Miller, Ian, MD and Flamini, Robert, MD and Wilfong, Angus, MD and Filloux, Francis, MD and Wong, Matthew, MD and Tilton, Nicole, CRNP and Bruno, Patricia, RN and Bluvstein, Judith, MD and Hedlund, Julie, RN and Kamens, Rebecca and Maclean, Jane, MD and Nangia, Srishti, MD and Singhal, Nilika Shah, MD and Wilson, Carey A, MD and Patel, Anup, MD and Cilio, Maria Roberta, Prof
Lancet Neurology, The, ISSN 1474-4422, 2016, Volume 15, Issue 3, pp. 270 - 278
Summary Background Almost a third of patients with epilepsy have a treatment-resistant form, which is associated with severe morbidity and increased mortality.... 
Neurology | CLOBAZAM | MEDICAL MARIJUANA | CLINICAL NEUROLOGY | HISTORY | Cannabidiol - administration & dosage | Outcome Assessment (Health Care) | Humans | Seizures - drug therapy | Child, Preschool | Anticonvulsants - administration & dosage | Cannabidiol - pharmacology | Infant | Male | Anticonvulsants - pharmacology | Lennox Gastaut Syndrome - drug therapy | Drug Resistant Epilepsy - drug therapy | Young Adult | Anticonvulsants - adverse effects | Cannabidiol - adverse effects | Adolescent | Age of Onset | Adult | Female | Epilepsies, Myoclonic - drug therapy | Drug Therapy, Combination | Child | Clinical trials | Marijuana | Drug therapy | Epilepsy | Children's hospitals | Mortality | Drugs | Studies | Convulsions & seizures | Pneumonia | Pain | Young adults | Medical marijuana | Families & family life | Diarrhea | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT(1A) and CB2 receptors
by Pazos, MR and Mohammed, N and Lafuente, H and Santos, M and Martinez-Pinilla, E and Moreno, E and Valdizan, E and Romero, J and Pazos, A and Franco, R and Hillard, CJ and Alvarez, FJ and Martinez-Orgado, J
NEUROPHARMACOLOGY, ISSN 0028-3908, 08/2013, Volume 71, pp. 282 - 291
The mechanisms underlying the neuroprotective effects of cannabidiol (CBD) were studied in vivo using a hypoxic-ischemic (HI) brain injury model in newborn... 
Pigs | Brain | Neuroprotection | ACTIVATION | Serotonin | PIGLET | Cannabidiol | REPERFUSION | BLOOD-FLOW | NEUROSCIENCES | ENCEPHALOPATHY | HETEROMERS | Cannabinoids | IN-VITRO | Newborn | TARGETS | PHARMACOLOGY & PHARMACY | CEREBRAL-ISCHEMIA | Hypoxia-ischemia | Neuroprotective Agents - therapeutic use | Neurons - pathology | Serotonin 5-HT1 Receptor Antagonists - pharmacology | Humans | Neuroprotective Agents - antagonists & inhibitors | Protein Multimerization | Receptor, Serotonin, 5-HT1A - genetics | Male | Cannabidiol - antagonists & inhibitors | Hypoxia-Ischemia, Brain - pathology | Receptor, Cannabinoid, CB2 - antagonists & inhibitors | Brain Injuries - physiopathology | Receptor, Cannabinoid, CB2 - genetics | Recombinant Fusion Proteins - metabolism | Brain - metabolism | Cannabinoids - pharmacokinetics | Hypoxia-Ischemia, Brain - etiology | Neuroprotective Agents - pharmacology | Neuroprotective Agents - pharmacokinetics | HEK293 Cells | Cannabinoid Receptor Antagonists - pharmacology | Cannabidiol - pharmacokinetics | Cannabidiol - therapeutic use | Neurons - metabolism | Neurons - drug effects | Cannabinoids - metabolism | Hypoxia-Ischemia, Brain - metabolism | Receptor, Serotonin, 5-HT1A - metabolism | Disease Models, Animal | Animals, Newborn | Nerve Tissue Proteins - antagonists & inhibitors | Hypoxia-Ischemia, Brain - drug therapy | Neurons - immunology | Cannabidiol - pharmacology | Random Allocation | Brain - drug effects | Nerve Tissue Proteins - metabolism | Receptor, Cannabinoid, CB2 - metabolism | Cannabinoids - therapeutic use | Animals | Receptor, Serotonin, 5-HT1A - chemistry | Reperfusion Injury - prevention & control | Brain - pathology | Brain - immunology | Sus scrofa
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain
by Johnson, Jeremy R., MB ChB and Burnell-Nugent, Mary, MB BChir and Lossignol, Dominique, MB ChB, MRCG, DRCOG and Ganae-Motan, Elena Doina, MD and Potts, Richard, BSc (Hons), MICR and Fallon, Marie T., MB ChB, MD, FRCP (E), FRCP (Glasg)
Journal of Pain and Symptom Management, ISSN 0885-3924, 2010, Volume 39, Issue 2, pp. 167 - 179
Abstract This study compared the efficacy of a tetrahydrocannabinol:cannabidiol (THC:CBD) extract, a nonopioid analgesic endocannabinoid system modulator, and... 
Anesthesia & Perioperative Care | Pain Medicine | cannabidiol | Sativex | pain | tetrahydrocannabinol | Cancer | CONTROLLED-TRIAL | CLINICAL NEUROLOGY | CANNABIS-BASED MEDICINE | NEUROPATHIC PAIN | MEDICINE, GENERAL & INTERNAL | CB1 | MULTIPLE-SCLEROSIS | DELTA-9-TETRAHYDROCANNABINOL | PHARMACOLOGY | CLINICAL-TRIALS | HEALTH CARE SCIENCES & SERVICES | DELTA-TETRAHYDROCANNABINOL | RECEPTORS | Sativex (R) | Pain, Intractable - drug therapy | Dronabinol - adverse effects | Pain, Intractable - etiology | Cannabidiol - administration & dosage | Double-Blind Method | Humans | Middle Aged | Male | Dose-Response Relationship, Drug | Neoplasms - complications | Cannabidiol - adverse effects | Endpoint Determination | Adult | Female | Aged | Cannabidiol - therapeutic use | Dronabinol - administration & dosage | Dronabinol - therapeutic use | Drug Combinations | Complications and side effects | Care and treatment | Sleep | Pain | Analgesics | Oncology, Experimental | Analysis | Clinical trials | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Neurological aspects of medical use of cannabidiol
by Mannucci, Carmen and Navarra, Michele and Calapai, Fabrizio and Ventura-Spagnolo, Elvira and Busardò, Francesco P and Cas, Roberto D and Ippolito, Francesca M and Calapai, Gioacchino
CNS and Neurological Disorders - Drug Targets, ISSN 1871-5273, 2017, Volume 16, Issue 5, pp. 541 - 553
Background: Cannabidiol (CBD) is among the major secondary metabolites of Cannabis devoid of the delta-9-tetra-hydrocannabinol psychoactive effects. It is a... 
Neurological | Neurology | Neuroprotection | Cannabidiol | Neurodegenerative diseases | NEURODEGENERATIVE DISORDERS | ARTERY OCCLUSION | INDUCED TOXICITY | PEDIATRIC EPILEPSY | neurological | NEUROSCIENCES | RAT MODEL | neurodegenerative diseases | MULTIPLE-SCLEROSIS | neuroprotection | IN-VIVO | VANILLOID TRPV1 | RESISTANT EPILEPSY | PHARMACOLOGY & PHARMACY | neurology | PARKINSONS-DISEASE | Neuroprotective Agents - therapeutic use | Animals | Neuroprotective Agents - chemistry | Neuroprotective Agents - pharmacology | Humans | Central Nervous System Diseases - drug therapy | Cannabidiol - pharmacology | Cannabidiol - therapeutic use | Cannabidiol - chemistry
Journal Article
Details down arrow
13. Full Text Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?
by Fernández‐Ruiz, Javier and Sagredo, Onintza and Pazos, M. Ruth and García, Concepción and Pertwee, Roger and Mechoulam, Raphael and Martínez‐Orgado, José
British Journal of Clinical Pharmacology, ISSN 0306-5251, 02/2013, Volume 75, Issue 2, pp. 323 - 333
Cannabidiol (CBD) is a phytocannabinoid with therapeutic properties for numerous disorders exerted through molecular mechanisms that are yet to be completely... 
cannabidiol | cannabinoid signalling system | neonatal ischaemia | Parkinson's disease | Huntington's disease | neuroprotection | Neuroprotection | Cannabidiol | Neonatal ischaemia | Cannabinoid signalling system | COLLAGEN-INDUCED ARTHRITIS | NEUROPROTECTIVE ANTIOXIDANTS | 5-HT1A RECEPTORS | CB2 RECEPTOR | HOUSE MUSK SHREW | NONPSYCHOACTIVE CANNABINOID CANNABIDIOL | IN-VITRO | PHARMACOLOGY & PHARMACY | DYSTONIC MOVEMENT-DISORDERS | HUNTINGTONS-DISEASE | PARKINSONS-DISEASE | Cannabidiol - pharmacology | Ischemia - drug therapy | Huntington Disease - drug therapy | Neurodegenerative Diseases - drug therapy | Humans | Cannabinoids - pharmacology | Enzymes | Epilepsy | Schizophrenia | Nervous system | Cannabinoids | Antipsychotic drugs | Huntington's chorea | Brain damage | Degeneration | Universities and colleges | Health aspects | Antianxiety agents | Medical Cannabidiol – Is There Anything It Can't Do?
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights